Erytra blood group analyser and kode technology testing of SARS‐CoV‐2 antibodies among convalescent patients and vaccinated individuals
Christof Weinstock(Universität Ulm), Stephen Henry(Auckland University of Technology), Chrysanthi Tsamadou(German Red Cross), Carolin Ludwig(German Red Cross), Willy A. Flegel(National Institutes of Health Clinical Center), Bernd Jahrsdörfer(Universität Ulm), Sabine Kaiser(Universität Ulm), Hubert Schrezenmeier(German Red Cross), Kshitij Srivastava, Nicolai V. Bovin
Cited by 9
Related Papers
The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
|New England Journal of Medicine|2006|1.3k
Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria
|Blood|2007|653
Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria
|Blood|2007|578
Molecular Basis of Weak D Phenotypes
|Blood|1999|336
Molecular Basis of Weak D Phenotypes
|Blood|1999|331